Sales growth driven by continued strong performance from Kisqali (+64% cc), Entresto (+22% cc), Kesimpta (+33% cc), Scemblix (+79% cc), Leqvio (+61% cc) and Pluvicto (+30% cc) Core operating income ...

Detailed price information for Bayer Aktienges ADR (BAYRY) from The Globe and Mail including charting and trades.

Among 20 patients with surgery- and radiation-refractory intracranial tumors, treatment with lutetium (Lu)-177 dotatate (Lutathera) was associated with a 6-month PFS rate three times higher than a ...

Novartis currently has two radiotherapies on the market, Pluvicto and Lutathera, which last year generated revenue of $980 million and $458 million, respectively.

Novartis strengthens expands its radioligand therapy arsenal with the acquisition of Mariana Oncology in a $1 billion deal. With this strategic move, Novartis has become a key player in the ...

The study reported a safety profile consistent with the adult population studied in NETTER-1, the pivotal trial for approval of Lutathera in adults, the company stated.

Novartis announced that the US Food and Drug Administration (FDA) approved Lutathera (USAN: lutetium Lu 177 dotatate / INN: lutetium (177Lu) oxodotreotide) for the treatment of paediatric patients 12 ...

Basel: Novartis has announced that the U.S. Food and Drug Administration (FDA) has approved Lutathera (USAN: lutetium Lu 177 dotatate / INN: lutetium (177Lu) oxodotreotide) for the treatment of ...

Novartis’ radioligand therapy Lutathera (lutetium Lu 177 dotatate) has been approved by the US Food and Drug Administration (FDA) to treat certain paediatric patients with neuroendocrine tumours (NETs ...

Accessed April 25, 2024. Novartis radioligand therapy Lutathera FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors (press release).

Lutathera is also approved in Europe for unresectable or metastatic, progressive, well-differentiated (G1 and G2), SSTR-positive GEP-NETs in adults, and in Japan for SSTR-positive NETs 8,9. Novartis ...